je.st
news
PTC Therapeutics Announces Expanded Access Program For Translarna (Ataluren)
2014-07-30 10:38:53| drugdiscoveryonline Home Page
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna™ (ataluren) available to patients before commercial availability in certain countries
Tags: program
access
expanded
announces
Category:Biotechnology and Pharmaceuticals